Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO


      News provided by

      WuXi Biologics

      Aug 18, 2026, 03:04 ET

      Share this article

      Share this article


      SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- BioPharma APAC recently published its Top 26 - Companies Leading Sustainable Biopharma Practices in 2026, highlighting leading sustainability practices across pharmaceutical companies, biotechnology firms and CRDMOs in Europe, North America and Asia Pacific, with a focus on Science Based Targets initiative (SBTi) commitments, value-chain decarbonization, green manufacturing, and sustainable operations. The list brings together global pharmaceutical leaders – such as MSD (Merck & Co.), Eli Lilly, Johnson & Johnson, AstraZeneca, Takeda, GSK and Bayer – collectively illustrating the diverse pathways through which players across the industry value chain are advancing the green transition, with WuXi Biologics was featured for its outstanding sustainability practices, reflecting international industry recognition of the Company's empowering contributions through green CRDMO.

      Sustainability is evolving from a corporate social responsibility requirement into an important driver of industry advancement and corporate competitiveness. For the biopharmaceutical industry, climate change, resource efficiency and supply-chain governance have become core areas of focus. More companies are seeking the best ways to answer a critical question: how can they pursue innovation and business growth while advancing a greener, lower-carbon and more sustainable development model?

      At WuXi Biologics, Green CRDMO is Sustainability in action

      The Company's Green CRDMO solution turns sustainability into an integrated capability that is practical, measurable and empowering, connecting sustainability progress with productivity, operational resilience and long-term competitiveness to create tangible and sustainable value for global clients.

      Across the global healthcare and biopharmaceutical value chain, sustainability is becoming a strategic priority for creating business value. Companies are expected to set science-based climate targets and net-zero commitments, reduce Scope 3 value-chain carbon emissions, quantify product carbon footprints, respond to global green procurement requirements, and disclose environmental performance with greater transparency. Green CRDMO solution is therefore not an add-on to traditional services, but a bridge that translates governance practices into business value by helping clients enhance corporate governance, reduce operating costs, capture green-financing opportunities, establish product-level carbon transparency, strengthen competitiveness in government procurement that emphasizes ESG performance, and improve overall supply-chain resilience.

      In Green Research, WuXi Biologics starts with "For Patients. For Planet." The Company leverages its integrated end-to-end CRDMO platform and innovative technologies to shorten the journey from molecule to patient. Discovery platforms such as WuXiBody™ accelerate the development of antibodies and complex molecules, improve developability and stability, and enable innovative therapies to reach patients faster, at greater scale and with higher quality. By simplifying bispecific antibody development and shortening R&D timelines by 6–18 months, WuXiBody™ improves R&D efficiency while reducing the natural resources and energy required to maintain research environments.

      In Green Development, WuXi Biologics uses advanced platforms including WuXia™, WuXiUP™ and WuXiUI™ to improve productivity, reduce resource use and provide more efficient and flexible process pathways for innovative biologics. The WuXia™ TrueSite cell line development platform further improves development efficiency and quality through technological innovation, achieving monoclonal antibody titers of 8–12 g/L — supporting high-yield commercial manufacturing requirements — and shortening to approximately six-month timeline from DNA to IND filing readiness. The WuXiUI™ ultra-intensified fed-batch platform boosts productivity by 3 to 8 times and reduces lifecycle environmental impacts by up to 60% compared with traditional fed-batch processes, making development lower-carbon, more efficient and more sustainable, while improving capacity, quality consistency and operational agility.

      In Green Manufacturing, WuXi Biologics leverages single-use technology (SUT) and process innovation to scale green manufacturing. Compared with traditional stainless-steel processes, SUT can save up to 70% of water, reduce resource use by approximately 33%, and lower negative climate-change impacts by approximately 40%. (End-of-life treatment accounts for only 1%–3% of its lifecycle environmental impact and is therefore negligible.) In addition, the Company remains committed to responsible waste management through zero waste to landfill, waste-to-energy utilization, continued reduction of SUT waste, and exploration of more environmentally friendly SUT recycling solutions. Combining WuXiUI™ with SUT can reduce the product carbon footprint per gram of protein by up to 80%, providing clients with manufacturing solutions that deliver both environmental and operational benefits. WuXi Biologics also uses lifecycle assessment (LCA) modeling and calculation capabilities to support its cradle-to-gate product carbon-footprint measurements and enable product-level carbon transparency. Clearer, traceable carbon data helps clients make better low-carbon decisions, manage Scope 3 emissions, and advance value-chain decarbonization.

      In Green Operations, WuXi Biologics embeds sustainability across its global operations, and uses lean management and digital tools to improve resource and energy efficiency, delivering further reductions in carbon emissions, water use and waste. Its Green CRDMO solution was selected as a United Nations Global Compact "20 Cases for 20 Years" corporate sustainability case. The WuXi Biologics Green CRDMO White Paper systematically shares practices across green research, development, manufacturing and operations, outlining 242 energy-saving cases covering 12 major energy systems and five key energy-saving scenarios across 25 categories of energy-saving technologies, and supporting the replication of green operational practices across global sites and the industry value chain.

      Climate action remains a central pillar of the Company's Green CRDMO strategy. WuXi Biologics has obtained SBTi validation for its near-term, long-term and net-zero targets, and has committed to achieving net-zero emissions across its value chain by 2050. To support these ambitions, the Company continues to advance energy efficiency initiatives, renewable energy adoption, green operations, and supply-chain collaboration. BioPharma APAC specifically highlighted WuXi Biologics' SBTi-approved targets and commitment to sustainable transformation within the biopharmaceutical industry.

      In recent years, WuXi Biologics has continued to receive international recognition for its sustainability performance, including the highest MSCI AAA ESG rating; the EcoVadis Platinum Medal, placing the Company in the global top 1%; inclusion in the Dow Jones Best-in-Class World Index and Dow Jones Best-in-Class Emerging Markets Index; CDP "A List" recognition for Climate Change, Water Security and Supplier Engagement Assessment; the highest "Negligible Risk" rating from Morningstar Sustainalytics and recognition as an ESG Industry and Regional ESG Leader; inclusion in the FTSE4Good Index Series; the ISS ESG Prime status; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index. These recognitions underscore the Company's progress across environmental, social and governance areas, as well as global stakeholder recognition of its sustainability strategy and performance.

      Green manufacturing is not only an important sustainability commitment, but also a key pathway to enhancing competitiveness, productivity and operational resilience.

      As a global leader in green biologics solutions, WuXi Biologics will continue to advance green technology innovation and create shared sustainable value for global partners through its end-to-end Green CRDMO solution, working with stakeholders across the value chain toward a greener and healthier future.

      About WuXi Biologics

      WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide*.

      With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients'needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

      WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

      For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

      *The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)
      *The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

      WuXi Biologics Contacts
      ESG
      [email protected]
      Media
      [email protected]

      SOURCE WuXi Biologics

      Modal title

      Also from this source

      WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence

      WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence

      WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two...

      WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026

      WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it received...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      Environmental Products & Services

      Environmental Products & Services

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.